Open House Biologics Discount Agreements 2026 - Epoetin theta
Original notice title
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 16 Epoetin theta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed turnover; actual demand depends on prescriptions and market share.
Requirement for qualified electronic signature or original signed copy may cause delays.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Conclusion of discount agreements for Epoetin theta
- Non-exclusive framework of uniform conditions
Show full summary
Open House procedure by Techniker Krankenkasse and associated health insurers to conclude discount agreements (Rabattverträge) for the active substance Epoetin theta. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (July 1, 2026 to June 30, 2028). No exclusivity, no individual negotiations, uniform conditions. The notice clarifies this is not a public procurement contract under EU Directive 2014/24/EU.
Risks
No guaranteed turnover; actual demand depends on prescriptions and market share.
Requirement for qualified electronic signature or original signed copy may cause delays.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG
- Valid marketing authorization for the offered medicinal product
- Seat in Germany, EU, or EEA
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Biologics Discount Agreements 2026 - Epoetin theta
Conclusion of discount agreements for the active substance Epoetin theta under § 130a Abs. 8 SGB V. Open to all eligible pharmaceutical entrepreneurs throughout the contract period.
Location
Duration
Category
Award Criteria
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Epoetin theta zu schließen.
Value note
Show original TED data
Original lot title
Open House Biologika Rabattverträge 2026 - 16 Epoetin theta
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Epoetin theta zu schließen.
Procurement Details
- Publication date
- 18 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 342625-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed turnover; actual demand depends on prescriptions and market share.
Requirement for qualified electronic signature or original signed copy may cause delays.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications